Pelthos Therapeutics M&A Deal with Castle Creek Biosciences, Inc.
Pelthos Therapeutics has entered into a definitive agreement to acquire Castle Creek Biosciences in a merger transaction. Castle Creek stockholders will receive 5.2 million shares of Pelthos common stock plus potential milestone payments totaling up to $300 million tied to the clinical and commercial success of the D-Fi gene therapy franchise. The deal combines Pelthos' commercial dermatology infrastructure with Castle Creek's late-stage cell and gene therapy platform for rare skin diseases.
- Counterparty
- Castle Creek Biosciences, Inc.